ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...100101102103104105106107108109110...129130»
  • ||||||||||  Soolantra (ivermectin) / Galderma
    Journal:  Development of microemulsion based topical ivermectin formulations: Pre-formulation and formulation studies. (Pubmed Central) -  Dec 20, 2020   
    Overall, microemulsion gel formulations exhibited better stability profiles than their microemulsion counterparts. All microemulsion gel formulations demonstrated significantly faster in vitro membrane permeation (release) rate of ivermectin than Soolantra cream (reference marketed product by Galderma, USA).The developed microemulsion and microemulsion gel formulations appear to be promising vehicles for topical delivery of ivermectin.
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Antimicrobial, anti-cancer, anti-filarial and anti-inflammatory activities of Cowabenzophenone A extracted from the endophytic fungus Aspergillus terreus isolated from a mangrove plant Bruguiera gymnorrhyza. (Pubmed Central) -  Dec 19, 2020   
    When the compound was tested in vitro for its ability to inhibit inflammations, α-glucosidase inhibitory activities and its antimicrobial properties, it showed an anti-inflammatory activity amounting to an IC50 of 12.1 µg/mL, α-glucosidase inhibitory activity, with IC50 values of 7.8 ± 0.5 μM, and antibacterial activity against Bacillus subtilis TISTR 088, and Bacillus cereus TISTR 688 with MIC values of 1 μg/mL and 2 μg/mL respectively. The compound showed cytotoxicity against HCT 116 colon cancer cell line with an IC50 value of 10.1 ?M, and also showed a considerably high potential towards anti-filarial activities by resulting MIC, IC50 and LC50 values of 0.358 ± 0.02 mg/mL, 0.708 ± 0.021 mg/mL and 3.89 ± 0.18 mg/mL, respectively, in comparison to the standard drug Ivermectin (IVM).
  • ||||||||||  ivermectin / Generic mfg.
    Clinical, Journal:  Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19. (Pubmed Central) -  Dec 19, 2020   
    This study sheds light on ivermectin-loaded, orally administrable, biodegradable nanoparticles to be a potential treatment option for the novel coronavirus through a multilevel inhibition. As both ACE2 targeting and the presence of spike protein are features shared among this class of virus, this platform technology has the potential to serve as a therapeutic tool not only for COVID-19 but for other coronavirus strains as well.
  • ||||||||||  ivermectin / Generic mfg.
    Review, Journal:  Demodex and ocular surface disease (Pubmed Central) -  Dec 17, 2020   
    Eyelid hygiene and oil-based ointments are the cornerstone of treatment. New specific treatments, in particular topical treatments based on tea tree oil, ivermectin, as well as pulsed light therapy and micro-exfoliation of the eyelid margin, can help to reduce the parasitic load and improve symptoms.
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Ivermectin inhibits extracellular vesicle secretion from parasitic nematodes. (Pubmed Central) -  Dec 17, 2020   
    Protein secretion was inhibited by IVM in the microfilariae stage, but not in any other stage tested. Our data provides evidence that inhibiting the secretion of immunomodulatory EVs by parasitic nematodes could explain, at least in part, IVM mode of action and provides a phenotype for novel drug discovery.
  • ||||||||||  ivermectin oral / Generic mfg.
    Trial completion:  SAINT: Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial (clinicaltrials.gov) -  Dec 17, 2020   
    P2,  N=24, Completed, 
    However, transmission is still ongoing, and heavily infected individuals are still found in communities, supporting why some individuals are still experiencing severe adverse events despite > 2 decades of CDTI in this Health District. Active, not recruiting --> Completed
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Opinions of key stakeholders on alternative interventions for malaria control and elimination in Tanzania. (Pubmed Central) -  Dec 16, 2020   
    While policy-makers, regulators and community members all noted their reliance on scientists to make informed decisions, their reasoning on the benefits and disadvantages of specific interventions included factors beyond technical efficiency. This study suggests the need to encourage and strengthen dialogue between research scientists, policy makers, regulators and communities regarding new interventions.